{
    "eu_pnumber": "____________",
    "atc_code": "____________",
    "eu_aut_status": "EXPIRED",
    "eu_brand_name_current": "EU/3/05/339",
    "status_type": "w",
    "eu_od_number": "EU/3/05/339",
    "active_substance": "Dasatinib",
    "eu_od_con": "Treatment of chronic myeloid leukaemia",
    "eu_od_sponsor": "Bristol-Myers Squibb Pharma EEIG",
    "eu_od_pnumber": "EU/1/06/363",
    "orphan_status": "o",
    "eu_od_date": "2005-12-23 00:00:00",
    "eu_aut_date": "2005-12-23 00:00:00",
    "eu_aut_type_initial": "NA_at_release_date",
    "eu_aut_type_current": "standard",
    "ema_od_number": "EMEA/OD/075/05",
    "ema_od_number_id": "75/05",
    "eu_referral": "False",
    "eu_suspension": "False",
    "ema_number_certainty": "1.0",
    "authorisation_row": "0",
    "scrape_date_web": "13/12/2022",
    "filedates": {
        "EU-3-05-339_o_dec_0.pdf": {
            "pdf_link": "https://ec.europa.eu/health/documents/community-register/2005/2005122310805/dec_10805_en.pdf",
            "pdf_date": "2005-12-23 00:00:00",
            "pdf_scrape_date": "2022-12-19 14:35:46.910395"
        }
    }
}